Startups

Our startups

Be inspired. Search our startups.

Filter
Startups
2017  Finalist
Medical Devices

Cellino’s goal is to enable gene therapy companies and research labs to deliver gene-editing cargo to cells with exceptional performance, which is a major challenge today.

2017  Finalist
Therapeutics (Pharma / Biotech)

47% of all dogs over the age of 10 will die from cancer. With current treatment options expensive and potentially leading to negative side effects, Torigen is focused on commercializing, VetiVax, a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight the cancer.

Using a surgically excised portion of tumor tissue, we create a series of treatments that are given back to the animal to help stimulate their immune system to fight cancer, safely and inexpensively.

2017  Finalist
Therapeutics (Pharma / Biotech)

ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions.

2017  Finalist
Medical Devices

Nerves injured by trauma or surgery, including amputation, often cannot be repaired. Nerve fibers attempt to reconnect to their former targets, but instead produce a tangled, swollen, and inflamed neuroma - a source of debilitating pain for 20-30% of the 1.7M existing amputees, and the 185k new cases/year. No standard of care exists to prevent neuroma formation or treat them. We have created NervLok, a patent-pending bioengineered device that is placed onto the cut nerve-end to prevent neuroma.

2017  Finalist
Therapeutics (Pharma / Biotech)

The widespread irreproducibility in biomedical science is making scientific ‘experts’ obsolete. Hive leverages an innovative model to extract information from the scientific literature on a large-scale while providing confidence metrics that directly assess reproducibility of scientific findings. Hive offers business development executives, venture capitalists, and researchers the extraordinary ability to develop their expertise on any topic in biomedicine within a short period of time.

2017  Finalist
Therapeutics (Pharma / Biotech)

We seek to accelerate the rate at which science becomes medicine by identifying and developing early-stage biological innovation. Our lead candidate — Nivien — is a small molecule kinase inhibitor that targets a previously-unaddressed biochemical pathway responsible for cancer resistance. We aim to enhance existing treatments by inactivating the downstream effects of this pathway.

2017  Finalist
Therapeutics (Pharma / Biotech)

Akanocure is developing a group of novel bio-inspired anti-cancer next generation small molecules (SGSM) that would have the affinities and elicit the protein-protein interaction modulation of macromolecules while retaining the high tumor permeability of small molecules. SGSM are designed to be inexpensive to develop, avoid the side effects of chemotherapy, elicit response in most patients, suppress metastasis and relapse, and could be synergistic when combined with immunotherapies.